A randomised trial of radiotherapy compared with cisplatin chemo-radiotherapy in patients with unresectable squamous cell cancer of the esophagus>

Radiotherapy and Oncology

Volumn 83, Issue 2, 2007, Pages 139-147

  Kumar, Shaleen ^a   Dimri, Kislay ^a   Khurana, Rohini ^a   Rastogi, Neeraj ^a   Das, Koilpillai Joseph Maria ^a   Lal, Punita ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Brachytherapy; Chemotherapy; Esophageal neoplasm; Radiotherapy

Indexed keywords

CISPLATIN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DYSPHAGIA; ESOPHAGUS CANCER; ESOPHAGUS STRICTURE; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; INTERMETHOD COMPARISON; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; TELETHERAPY; TREATMENT FAILURE; ULCER;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; BRACHYTHERAPY; CARCINOMA, SQUAMOUS CELL; CHI-SQUARE DISTRIBUTION; CISPLATIN; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY DOSAGE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 34248671408     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2007.03.013     Document Type: Article

References (28)

1. Cominos M., Mosleh-Shirazi M.A., Tait D., Henrys A., and Cornes P. Quantification and reduction of cardiac dose in radical radiotherapy for oesophageal cancer. Br J Radiol 78 (2005) 1069-1074
2. Cooper J.S., Guo M.D., Herskovic A., et al. Chemoradiotherapy of locally advanced esophageal cancer. Long term follow-up of a prospective randomised trial (RTOG 85-01). JAMA 281 (1999) 1623-1627
3. Cox J.D., Stetz J., and Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31 (1995) 1341-1346
4. Datta N.R., Kumar S., Nangia S., Hukku S., and Ayyagari S. A non randomized comparison of two radiotherapy protocols in inoperable squamous cell carcinoma of the oesophagus. Clin Oncol 10 (1998) 306-312
5. Enzinger P.C., and Mayer R.J. Esophageal cancer. N Engl J Med 349 (2003) 2241-2252
6. Fowler J.F. The linear-quadratic model and progress in fractionated radiotherapy. Br J Radiol 62 (1989) 679-684
7. Gaspar L.E., Nag S., Herskovic A., Mantravadi R., Speiser B., and the Clinical Research Committee, American Brachytherapy Society, and Philadelphia PA. American Brachytherapy Society (ABS) consensus guidelines for brachytherapy of esophageal cancer. Int J Radiat Oncol Biol Phys 38 (1997) 127-132
8. Gaspar L.E., Winter K., Kocha W.I., Coia L.R., Herskovic A., and Graham M. A phase I/II study of external beam radiation, brachytherapy and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207). Cancer 88 (2000) 988-995
9. Hall E.J. Radiobiology for the radiologist. 5th ed. (2000), Lippincott, Philadelphia
10. Herskovic A., Martz K., Al-Sarraf M., et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326 (1992) 1593-1598
11. Hong T.S., Crowley E.M., Killoran J., and Mamon H.J. Considerations in treatment planning for esophageal cancer. Semin Radiat Oncol 17 (2007) 23-61
12. Ishikura S., Nihei K., Ohtsu A., et al. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol 21 (2003) 2697-2702
13. Kumar S., Dimri K., Datta N.R., et al. Safety and efficacy of concurrent cisplatin and radiotherapy in inoperable or metastatic squamous cell esophageal cancer. Acta Oncologica 41 (2002) 457-462
14. Kumar S, Lal P. Comment on: short course palliative radiotherapy of 20 Gy in 5 fractions for advanced and incurable head and neck cancer: AIIMS study [Radiother Oncol 2004;71:275-80] Radiother Oncol 2005;74:75-9.
15. Kumar S., Pandey M., Lal P., Rastogi N., Maria Das K.J., and Dimri K. Concomitant boost radiotherapy with concurrent weekly cisplatin in advanced head and neck cancers: a phase II trial. Radiother Oncol 75 (2005) 186-192
16. Marcu L., Bezak E., and Olver I. Scheduling cisplatin and radiotherapy in the treatment of squamous cell carcinomas of the head and neck: a modelling approach. Phys Med Biol 51 (2006) 3625-3637
17. Marcu L., van Doorn T., and Olver I. Cisplatin and radiotherapy in the treatment of locally advanced head and neck cancer-a review of their cooperation. Acta Oncol 42 (2003) 315-325
18. Minsky B.D., Pajak T.F., Ginsberg R.J., et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high dose versus standard-dose radiation therapy. J Clin Oncol 20 (2002) 1167-1174
19. Okawa T., Dokiya T., Nishio M., Hishikawa Y., Morita K., and and Japanese Society Of Therapeutic Radiology and Oncology (JASTRO) Study Group. Multi institutional randomized trial of external radiotherapy with and without intralumenal brachytherapy for esophageal cancer in Japan. Int J Radiat Oncol Biol Phys 45 (1999) 623-628
20. Sharma V., Agarwal J., Dinshaw K., et al. Late esophageal toxicity using a combination of external beam radiation, intralumenal brachytherapy and 5-fluorouracil infusion in carcinoma of the esophagus. Dis Esoph 13 (2000) 219-225
21. Sur R.K., Kochhar R., Negi P.S., and Gupta B.D. High dose rate intralumenal brachytherapy in palliation of esophageal carcinoma. Endocuriether/Hyperther Oncol 10 (1994) 25-29
22. Sur R.K., Singh D.P., Sharma S.C., et al. Radiation therapy of esophageal cancer: role of high dose rate brachytherapy. Int J Radiat Oncol Biol Phys 22 (1992) 1043-1046
23. Vuong T., Szego P., David M., et al. The safety and usefulness of high-dose-rate endolumenal brachytherapy as a boost in the treatment of patients with esophageal cancer with external beam radiation with or without chemotherapy. Int J Radiat Oncol Biol Phys 63 (2005) 758-764
24. Wilson G.D., McNally N.J., Dische S., et al. Measurements of cell kinetics in human tumor in vivo using bromodeoxyuridine incorporation and flow cytometry. Br J Cancer 58 (1988) 423-431
25. Wong R, Malthaner R. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev 2006:CD002092.
26. Wong R.K.S., Malthaner R.A., Zuraw L., Rumble R.B., and and the Cancer Care Ontario Practice Guidelines Initiative Gastrointestinal Cancer Disease Site Group. Combined modality radiotherapy and chemotherapy in the non-surgical management of localised carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 55 (2003) 930-942
27. Yin, W. Brachytherapy of carcinoma of the esophagus in China, 1970-1974 and 1982-1984. In: Martinez AA, Orton CG, Mould RF, editors. Brachytherapy HDR and LDR. Proceeding of the brachytherapy meeting, Remote afterloading: state of the art, 1989, Dearborn, MI, USA. Columbia, USA: Nucletron Corp.; 1990. p. 52-6.
28. Yorozu A., Dokiya T., and Oki Y. High-dose-rate brachytherapy boost following concurrent chemoradiotherapy for esophageal carcinoma. Int J Radiat Oncol Biol Phys 45 (1999) 271-275